Janssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Light Chain (AL) Amyloidosis

MLA

“Janssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO (Daratumumab and Hyaluronidase-Fihj) for the Treatment of Patients with Light Chain (AL) Amyloidosis.” Legal Monitor Worldwide, 12 Sept. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.635207536&authtype=sso&custid=ns315887.

APA

Janssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Light Chain (AL) Amyloidosis. (2020, September 12). Legal Monitor Worldwide.

Chicago

Legal Monitor Worldwide. 2020. “Janssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO (Daratumumab and Hyaluronidase-Fihj) for the Treatment of Patients with Light Chain (AL) Amyloidosis,” September 12. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.635207536&authtype=sso&custid=ns315887.